TY  - JOUR
PY  - 2004//
TI  - Pegylated interferons
JO  - Journal of Drug Evaluation
A1  - D'Souza, R.
A1  - Foster, G.R.
SP  - 113
EP  - 127
VL  - 2
IS  - 4
N2  - PEG-interferons have improved pharmacokinetics by allowing a once-weekly dosing regimen that provides constant and sustained therapeutic plasma concentrations, and, as a result, a constant and sustained antiviral pressure over the entire dosing period. This in turn, leads to PEG-IFN having significantly improved response rates over conventional IFN in patients suffering from chronic hepatitis B and C, and it is likely that the improved response rates with these new compounds will lead to more patients eradicating these life threatening viruses. © 2004 Parthonon Publishing.<p /> <p>Language: en</p>
LA  - en
SN  - 1479-1137
UR  - http://dx.doi.org/10.1080/14791130400023643
ID  - ref1
ER  -